- Rating
- 2
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 2
Read review
Paper summary
HiMarket is a hierarchical predictive representation learning framework for stock selection, dividing stock representation into three parts: global, dynamic grouping, and individual stock residuals. In the pre-training phase, the model first predicts the future shared market state, then uses this as a condition to predict individual stock residuals, and uses an EMA teacher model to provide the training objective. In the downstream phase, the model uses a Factor-Query module to extract information from historical market states by combining stock representations and residuals, and performs fine-tuning of stock ranking.
The paper compares HiMarket with 14 baseline configurations on NASDAQ, NYSE, and CSMD300. Results show that HiMarket achieves the highest cumulative return on all three datasets and the highest Sharpe ratio on NASDAQ and NYSE.
Critical strengths
-
Coherent Methodology. Global, grouping, and residual decomposition, combined with market state condition prediction and individual stock query modules, form a clear framework. The paper explicitly distinguishes between pre-training and downstream ranking, demonstrating that these representations are not necessarily independent or correspond to identifiable economic factors.
-
Strong Experimental Results and Some Ablation Evidence. HiMarket achieved competitive results on three datasets. Table 3 shows that performance decreased after removing the pre-training or Factor-Query modules, indicating that both contribute to the overall model. The paper's architecture diagram and training details are also clear.
Critical weaknesses
-
The contributions of the core mechanisms are not adequately differentiated. Table 3 demonstrates the effectiveness of the overall framework, but fails to separately prove the individual roles of hierarchical decomposition and market state condition residual prediction. Specifically, "Plain JEPA + Linear Readout" alters both the pre-training method and the downstream prediction head. Furthermore, the paper lacks ablation experiments that separately remove residual information from dynamic grouping, predicted state conditions, and queries. Therefore, it remains unclear which core designs truly contribute to performance improvements.
-
The evaluation protocol and baseline comparability remain unclear. Table 2 does not clearly distinguish which baselines were reproduced by the authors and which directly cite results from existing papers. It is also unclear whether the methods use the same input features, preprocessing, data partitioning, stock validity screening, and portfolio rules. Section 5.1 defines the candidate stock pool using effective next-day return labels. If the validity of future labels affects stock selection, it may introduce forward bias. Additionally, the daily adjusted Top-5 portfolio does not account for transaction costs, slippage, and execution latency, limiting the practical interpretation of the return results. These issues do not prove that the results are wrong, but they do indicate that there are still important details in the assessment that need to be verified.
Questions for authors
-
Can you remove the dynamic grouping, market state prediction conditions, and residual information from stock queries while keeping other settings unchanged to verify the contribution of each module?
-
Which baselines were rerun by the authors, and which cited existing papers? Did they use the same data partitioning, features, preprocessing, stock efficiency screening, and portfolio rules?
-
Is the Top-5 candidate stock pool entirely determined by information known at the time of decision-making? How do you handle the issue of missing next-day return labels? Can you supplement the performance under turnover rate and non-zero transaction fees?
3 comments
Response to Reviewer wXxA (Part 2/2)
Q2. Baseline sources and comparability
Were all baseline results in Table 2 obtained using identical data splits, input features, preprocessing procedures, stock-availability masks, and portfolio evaluation rules? If some results were taken from previous studies, please clarify their sources and comparability.
Response. We follow the SSPT benchmark for NASDAQ and NYSE and adopt the baseline and Market results from Table 2 of SSPT. All CSMD300 baseline results are obtained from our own experiments. HiMarket is trained and evaluated by us on all three datasets.
We will identify result sources by dataset in the table caption and describe the corresponding experimental settings in the appendix.
The U.S. evaluation follows SSPT's chronological benchmark and daily equal-weighted Top-5 close-to-close protocol. The local CSMD300 experiments share the same frozen panel, chronological splits, and portfolio evaluation rules, with model-specific feature processing. The appendix will specify the input features, preprocessing, and stock-availability rules. We have also added local supplementary comparisons under a common execution and fee protocol, as discussed in Q3.
Q3. Stock eligibility, missing labels, turnover, and costs
Is stock eligibility for the daily Top-5 portfolio determined exclusively using information available before the target trading day? In particular, how is missing next-day return-label availability handled without affecting the eligible universe at decision time? Can the authors also report portfolio turnover and performance under nonzero transaction costs?
Response. The original portfolio evaluator required an available next-day return label before a stock could enter the Top-5 holdings. This makes the evaluation universe depend on future label availability. We have added an evaluation in which historical observations determine eligibility, return-label availability is used for retrospective prediction metrics, and opening quotes determine whether orders can execute.
For the executable-price backtest, inputs end at the close of day t−1, orders execute at the open of t, and rebalancing occurs at the open of t+1. We reuse the original prediction scores. A missing opening quote prevents the corresponding order from executing. Unspent funds remain in cash, unsold holdings are retained, and existing positions are valued using the last available quote. Orders, cash, holdings, and fees are recorded in a daily ledger.
The table reports HiMarket's results under this open-to-open schedule. Each performance cell gives cumulative IRR / annualized SR.
| Dataset | Zero fees | Buy 5 / sell 15 bps |
|---|---|---|
| NASDAQ | 49.39% / 1.728 | 28.71% / 1.044 |
| NYSE | 55.50% / 2.359 | 9.55% / 0.568 |
| CSMD300 | 39.64% / 1.829 | 17.12% / 1.001 |
The 5/15 bps buy/sell schedule follows the Qlib CSI300 example and is applied here as a common cost-sensitivity scenario across markets. Fees are charged on actual traded amounts, including initial entry, rebalancing, and final liquidation. Under this fee schedule, HiMarket has positive net returns and SR on all three datasets.
Thank you for the response and additional experiments. The new ablations largely address my concerns about the individual components. I also appreciate the authors' acknowledgment of the future-label issue in the original evaluation and the revised backtest.
However, I will maintain my rating of 2 (Weak rejection) for two reasons. First, under the revised protocol with transaction costs, HiMarket's advantage is less convincing. On CSMD300, StockMixer achieves higher returns and Sharpe ratio (18.22% / 1.083 vs. 17.12% / 1.001). On NYSE, HiMarket only slightly outperforms HIST (9.55% / 0.568 vs. 9.46% / 0.517). Second, the new component ablations still use the original zero-cost, close-to-close protocol. They support the proposed design, but do not establish whether the same gains hold under the corrected evaluation. The response strengthens the paper, but the remaining evidence does not change my overall assessment.
Response to Reviewer wXxA (Part 1/2)
We thank the reviewer for recognizing the motivation and coherence of HiMarket. We address the requests for controlled ablations, baseline provenance, and a verifiable portfolio evaluation protocol below. IRR denotes cumulative return and SR denotes annualized Sharpe ratio.
Q1. Controlled ablations
Response. We have extended the controlled ablations to all three datasets (NASDAQ, NYSE, and CSMD300), using consistent chronological splits, input processing, and validation-based checkpoint selection. All results follow the original zero-fee, daily equal-weighted Top-5 close-to-close protocol. We distinguish the matched encoder comparison from the component ablations, as they use different transfer settings.
1. Pretrained encoder comparison. To address the readout confound in the original "Plain JEPA + Linear Readout" comparison, we transfer only the pretrained encoder from each method. The downstream hierarchical aggregator, statistics projection, and stock-ranking readout use identical architectures and initializations, with the same fine-tuning protocol.
HiMarket achieves higher IRR and SR across all three datasets under matched downstream conditions, providing controlled evidence for the effectiveness of its pretraining scheme. This comparison transfers only the encoder and therefore uses a different reference from the Full-model component ablations below.
2. Hierarchical component ablations. We separately examine dynamic grouping, group-level information, forecast market-state conditioning, and residual-aware stock queries. The affected training stages are retrained rather than modifying an already fine-tuned Full model only at inference time.
Together, these experiments provide complementary evidence for HiMarket's hierarchical design. The matched encoder comparison supports the effectiveness of its pretraining scheme, while the component ablations distinguish the contributions of adaptive grouping, group-level representations, forecast market-state conditioning, and residual-aware queries.